Case... August 2008
Wyeth Discovery Research: R&D Consortium Why Denmark? "Wyeth has a global vision of leading the way by curing diseases through innovative research. We have a large ongoing research program in the field of neuroscience and within this field of life science research, we are amongst other things interested in finding a cure for Parkinson's Disease. In order to assist us in our research efforts we are continuously on the lookout for leading technologies and world-class science. For a targeted and innovative discovery research program for Parkinson's Disease, we found this in Denmark. The CureND consortium led by Danish Professor Dr. Daniel Otzen is truly collaborative in nature and we expect great scientific progress to come from this joint effort." Soren Andersen, Vice President, Discovery Research, Wyeth Pharmaceuticals Inc. USA
Wyeth Discovery Research is part of Wyeth Inc., the 9. largest pharmaceutical company in the World. Wyeth was established in 1926 and is a world leader in pharmaceuticals, consumer health care products, and animal health care products. Wyeth operates in more than a 100 countries, is headquartered in Madison, New Jersey and employs more than 50.000 people worldwide.
CASE: Wyeth Discovery Research - R&D Consortium
The reasons for choosing Denmark: • Unique research capability in Parkinson’s disease • Access to a public-private collaboration model • Access to an excellent research community on all levels • Denmark’s competitiveness as one of the leading CNS centres in Europe The research project will focus on identifying novel, disease-modifying treatments to halt the progression of Parkinson’s disease, one of the most common, chronic neurodegenerative diseases in the elderly. The research consortium will be led by Professor Daniel Otzen formerly employed by Aalborg University now employed at the iNANO center at Aarhus University and Dr. Peter Reinhart, Head of Neurodegenerative Disease Research within Discovery Neuroscience at Wyeth Pharmaceuticals. The consortium will take advantage of a long history of science and innovation in Denmark in the field of Central Nervous System Disorders and biotech drug discovery. The total value of the CURE-ND collaboration exceeds $7M in public and private funding over 3 years.
I nt .
P r od u
ing t test rke Ma
R e s e a r ch
l ica ti o n
Wyeth Discovery Research has placed a line of their research- and development activities in Denmark, co-operating with the universities of Aalborg and Aarhus and in particular Professor Dr. Daniel Otzen, to gain new knowledge and to develop a new medicine for Parkinson’s disease. The collaboration model applied is an “Innovation consortium”, in which private industry, academia and public authorities join forces to make scientific advances. For the first time, an innovation consortium now has the participation of a major global pharmaceutical company.
Denmark at a glance • World's Best Place to conduct business in a five year perspective (Economist Intelligence Unit, 2008) • No. 3 on the Global Competitiveness Index (World Economic Forum, 2007-2008) • No. 1 in the world on the basis of flexible labour regulations (IMD, 2008) • No. 1 in the world on E-readiness (The Economist Intelligence Unit, 2007) • Highest worker motivation in the world (IMD, 2008) • No. 1 in the world on foreign investors liberty to aquire control in domestic companies (IMD, 2008) Whether your company considers to relocate, consolidate, set up new production facilities, is on the lookout for new innovation partners or other strategic business solutions in Europe, Invest in Denmark is a good place to begin. We provide customised information and services free of charge and in full confidentiality.
Invest in Denmark 2, Asiatisk Plads DK-1448 Copenhagen K Tel. +45 33 92 11 16 Fax +45 33 92 07 17
The information stated in this fact sheet may contain errors or omissions. Invest in Denmark and our co-operation partners disclaim any and all liability for any loss or damage caused by such errors or omissions.